Barclays Maintains Overweight on Eli Lilly, Raises Price Target to $810
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Geoff Meacham maintains an Overweight rating on Eli Lilly (LLY) and raises the price target from $680 to $810.
February 07, 2024 | 7:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays analyst Geoff Meacham maintains an Overweight rating on Eli Lilly and raises the price target from $680 to $810.
The increase in price target by Barclays reflects a positive outlook on Eli Lilly's stock, suggesting potential upside. This could lead to increased investor confidence and a possible short-term price increase.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100